Provided by Tiger Trade Technology Pte. Ltd.

Bioxcel Therapeutics Inc.

0.1628
-0.0186-10.25%
Post-market: 0.1550-0.0078-4.79%17:38 EDT
Volume:10.62M
Turnover:1.69M
Market Cap:5.10M
PE:-0.05
High:0.1700
Open:0.1509
Low:0.1415
Close:0.1814
52wk High:4.29
52wk Low:0.1415
Shares:31.31M
Float Shares:26.89M
Volume Ratio:0.84
T/O Rate:39.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1505
EPS(LYR):-5.7255
ROE:-1766.94%
ROA:-102.43%
PB:-0.04
PE(LYR):-0.03

Loading ...

BioXcel Therapeutics enrolls first patients in BXCL501 trial

TIPRANKS
·
Apr 08

BioXcel enrolls first patients in DoW-funded Phase 2a BXCL501 acute stress trial

Reuters
·
Apr 08

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of Bxcl501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

THOMSON REUTERS
·
Apr 08

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of Igalmi® in the at-Home Setting

THOMSON REUTERS
·
Apr 01

BioXcel Therapeutics Inc - FDA Assigns Pdufa Target Action Date of November 14, 2026 for Igalmi Application - SEC Filing

THOMSON REUTERS
·
Apr 01

BioXcel says FDA accepts IGALMI sNDA for at-home agitation treatment

Reuters
·
Apr 01

Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI)

TIPRANKS
·
Mar 30

BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 28

AI-driven biopharma firm BioXcel Therapeutics posts lower-than-expected Q4 loss on reduced SG&A costs

Reuters
·
Mar 27

BioXcel Therapeutics FY2025 net revenue drops 72% to $642,000; net loss widens to $69.9 million

Reuters
·
Mar 27

BRIEF-BioXcel Therapeutics Q4 Basic EPS USD -0.58 Vs. IBES Estimate USD -0.75

Reuters
·
Mar 27

BioXcel Therapeutics Q4 Revenue USD 256 Thousand VS. Ibes Estimate USD 162 Thousand

THOMSON REUTERS
·
Mar 27

BioXcel Therapeutics Q4 Operating Expenses USD 10.538 Million

THOMSON REUTERS
·
Mar 27

BioXcel Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters
·
Mar 23

BioXcel Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Mar 17

BioXcel Therapeutics Closes $8.0 Million Direct Offering

MT Newswires Live
·
Mar 12

Press Release: BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Dow Jones
·
Mar 12

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

THOMSON REUTERS
·
Mar 11

Why Are BioXcel Therapeutics Shares Down Friday?

Benzinga_recent_news
·
Mar 06

BUZZ-U.S. STOCKS ON THE MOVE -Burlington Stores, Berkshire Hathaway, Bioventus

Reuters
·
Mar 05